Related Experiment Video

Updated: May 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

MDV3100 for the treatment of prostate cancer

Deborah Mukherji1, Carmel J Pezaro, Johann S De-Bono

  • 1Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.

Expert Opinion on Investigational Drugs
|January 11, 2012
PubMed
Abstract

Insights

MDV3100, a novel androgen receptor antagonist, shows promise for advanced prostate cancer. It appears well-tolerated and may be a valuable addition to existing treatments for metastatic castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) treatment landscape is rapidly evolving.
  • MDV3100 is a novel androgen receptor antagonist demonstrating survival benefits in mCRPC patients previously treated with docetaxel.
  • Several other novel therapies have also shown improved overall survival in advanced prostate cancer.

Purpose of the Study:

  • To review the historical context of androgen deprivation therapy.
  • To discuss recently approved agents for advanced prostate cancer.
  • To analyze the clinical development and potential role of MDV3100 in future treatment protocols.

Main Methods:

  • Literature review of androgen deprivation therapy.
  • Analysis of clinical trial data for MDV3100.
  • Evaluation of MDV3100's safety and efficacy profile.

Main Results:

  • MDV3100 has shown improved survival in men with mCRPC.
  • The drug appears well-tolerated in clinical studies.
  • MDV3100 represents a new therapeutic option for advanced prostate cancer.

Conclusions:

  • MDV3100 is a promising new drug for advanced prostate cancer.
  • While awaiting full data, it seems to be a safe and effective treatment option.
  • MDV3100 expands the therapeutic choices for patients with mCRPC.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...